PALATIN ANNOUNCES PHASE 3 PL9643 MELODY-1 DRY EYE DISEASE CLINICAL DATA RESULTS PRESENTED AT AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY 2024 : vimarsana.com
CRANBURY - Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today...